Senti Biosciences, Inc.

SNTI Nasdaq CIK: 0001854270

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO, CA, 94080
Phone (650) 239-2030
Fiscal Year End 1231
EIN 862437900

Financial Overview

FY2025

$66.91M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events April 1, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment March 31, 2026 View on SEC
10-K Annual financial report March 27, 2026 View on SEC
8-K Current report of material events March 27, 2026 View on SEC
8-K Current report of material events March 19, 2026 View on SEC
4 Insider stock transaction report March 11, 2026 View on SEC
4 Insider stock transaction report March 11, 2026 View on SEC
4 Insider stock transaction report February 3, 2026 View on SEC
4 Insider stock transaction report February 3, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment January 20, 2026 View on SEC

Annual Reports

10-K March 27, 2026
  • SENTI-202 treatment for AML showed 50% patient response rate with 42% achieving complete remission.
  • FDA granted Orphan Drug Designation and RMAT status, accelerating the path to potential approval.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.